A Randomized, Open-Label, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with and/or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 17 Sep 2018
At a glance
- Drugs Avelumab (Primary) ; Carboplatin; Paclitaxel
- Indications Ovarian cancer
- Focus Registrational; Therapeutic Use
- Acronyms JAVELIN Ovarian 100
- Sponsors Pfizer
- 31 Aug 2018 Biomarkers information updated
- 19 May 2018 Status changed from recruiting to active, no longer recruiting.
- 04 Apr 2017 Planned End Date changed from 6 Sep 2019 to 1 Dec 2021.